November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Neeraj Agarwal: Changing the diagnostic paradigm of ccRCC
Nov 12, 2024, 18:46

Neeraj Agarwal: Changing the diagnostic paradigm of ccRCC

Neeraj Agarwal, Professor of Medicine and Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute, shared a post on X about a recent paper by him and colleagues published in Med by Cell Press:

“[89Zr]Zr-girentuximab PET-CT imaging to diagnose, characterize, and differentiate clear-cell renal cell carcinoma”

Authors: Chadi Hage Chehade, Georges Gebrael, Neeraj Agarwal.

Neeraj Agarwal: Changing the diagnostic paradigm of ccRCC

“Just in Med by Cell Press.

Excellent viewpoint by our trainee, Chadi Hage Chehade.

The novel Zirconium-girentuximab PET-CT is set to change the diagnostic paradigm of ccRCC kidney cancer (akin to PSMA-PET in prostate cancer).”

Shilpa Gupta, Director of Genitourinary Oncology, a staff member in Hematology and Oncology and a Professor of Medicine at Cleveland Clinic, shared this post, adding:

“Congrats Chadi Hage Chehade and super mentor Neeraj Agarwal on this very elegant viewpoint!

The productivity of the GU Team at Huntsman Cancer Center under Neeraj Agarwal’s leadership is extraordinary!”

More posts featuring Neeraj Agarwal and Shilpa Gupta.

Neeraj Agarwal is a Professor of Medicine, and a Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), University of Utah. He also directs the Genitourinary Oncology (GU) Program, and the Center of Investigational Therapeutics (CIT) at the HCI.

Dr. Agarwal is an Advisor to the Oncology Drug Advisory Committee and the United States Food and Drug Administration, leads early therapeutics in the SWOG genitourinary cancers committee, and is the Chief Editor of ASCO Daily News.

Shilpa Gupta is the Director of Genitourinary Oncology, a staff member in Hematology and Oncology and a Professor of Medicine at Cleveland Clinic. Dr. Gupta’s extensive research focuses on novel drug development and biomarkers of response/resistance in bladder cancer, contributing to numerous published works and leadership roles in clinical trials.